Pneumology - Original Articles Open access

Latent tuberculosis infection in patients with psoriasis using biologic therapies

Authors

Published
26 June 2025
Section
Pneumology - Original Articles
DOI
10.4081/monaldi.2025.3538

Abstract

Some studies have demonstrated a high prevalence of latent tuberculosis infection (LTBI) in patients with psoriasis and a higher risk of active tuberculosis (TB) in patients with severe psoriasis. The objective of this study is to identify the prevalence of LTBI before starting treatment with different biologicals and to identify the prevalence of LTBI and active TB while using these medications. We conducted a cross-sectional study with retrospective data collection in the outpatient department of dermatology at a general, tertiary care, university-affiliated hospital. The electronic medical records of all adult patients (≥18 years old) with psoriasis undergoing treatment with biologics were reviewed, and information about psoriasis, the type of biological therapy used, and the tuberculin skin test (TST) results were collected. The patients included had an indication for the TST test according to the Ministry of Health. In total, 126 patients were included in the study. The median duration of disease was 20 years. A total of 31 patients (24.6%) had LTBI diagnosed at screening before the use of biologicals, and an additional 17 (17.9%) patients had a diagnosis of LTBI during biological therapy. There were no cases of active TB during treatment with biologicals. There was no difference in the prevalence of LTBI during treatment with tumor necrosis factor inhibitors, interleukin (IL)-17 inhibitors, IL-23 inhibitors, and IL-12/23 inhibitors (p=0.228). In conclusion, we found that 24.6% of patients with psoriasis in an endemic TB region had LTBI. Additionally, 16.8% had a diagnosis of LTBI during biological therapy. Our data corroborate the recommendation that patients who live in high TB incidence settings should be tested annually for LTBI.

Keywords

Ethics Approval

The study was approved by the Ethics Committee at HCPA (number 20210431).

References

  1. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol 2017;31:205-12. DOI: https://doi.org/10.1111/jdv.13854
  2. Boehncke WH, Schön MP. Psoriasis. Lancet 2015;386:983-94. DOI: https://doi.org/10.1016/S0140-6736(14)61909-7
  3. Ministério da Saúde. Protocolo clínico e diretrizes terapêuticas psoríase. 2020. Available from: https://www.gov.br/conitec/pt-br/midias/relatorios/2021/20211021_relatorio_652_pcdt_psoriase.pdf. [Protocol in Portuguese].
  4. Nogueira M, Warren RB, Torres T. Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm change. J Eur Acad Dermatol Venereol 2021;35:824-34. DOI: https://doi.org/10.1111/jdv.16866
  5. Ocguder A, Tosun Ö, Akkurt O, Oguz T, Colakoglu T. Tuberculosis of the foot: a rare involvement in osteoarticular tuberculosis. J Clin Rheumatol 2006;12:304-5. DOI: https://doi.org/10.1097/01.rhu.0000250297.26149.8a
  6. Bordignon V, Bultrini S, Prignano G, et al. High prevalence of latent tuberculosis infection in autoimmune disorders such as psoriasis and in chronic respiratory diseases, including lung cancer. J BIol Regl Homeost Agents 2011;25:213-20.
  7. Romiti R, Carvalho AVE de, Duarte GV. Brazilian consensus on psoriasis 2020 and treatment algorithm of the Brazilian Society of Dermatology. An Bras Dermatol 2021;96:778-81. DOI: https://doi.org/10.1016/j.abd.2021.03.007
  8. Romiti R, Valenzuela F, Chouela EN, et al. Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis. Br J Dermatol 2019;181:202-3. DOI: https://doi.org/10.1111/bjd.17604
  9. Torres T, Chiricozzi A, Puig L, et al. Treatment of psoriasis patients with latent tuberculosis using IL-17 and IL-23 inhibitors: a retrospective, multinational, multicentre study. Am J Clin Dermatol 2024;25:333-42. DOI: https://doi.org/10.1007/s40257-024-00845-4
  10. Ministério da Saúde. Boletim epidemiológico - Tuberculose (2024). Available from: https://www.gov.br/aids/pt-br/central-de-conteudo/boletins-epidemiologicos/2024/boletim-epidemiologico-tuberculose-2024/view. [Report in Portuguese].
  11. Rossato Silva D, Rabahi MF, Sant'Anna CC, et al. Diagnosis of tuberculosis: a consensus statement from the Brazilian Thoracic Association. J Bras Pneumol 2021;47:e20210054. DOI: https://doi.org/10.36416/1806-3756/e20210054
  12. Ministério da Saúde. Manual de recomendações para o controle da tuberculose no Brasil. 2019. Available from: https://bvsms.saude.gov.br/bvs/publicacoes/manual_recomendacoes_controle_tuberculose_brasil_2_ed.pdf. [Material in Portuguese].
  13. Sánchez-Moya AI, García-Doval I, Carretero G, et al. Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain. BIOBADADERM registry. J Eur Acad Dermatol Venereol 2013;27:1366-74. DOI: https://doi.org/10.1111/jdv.12011
  14. Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009;33:956-73. DOI: https://doi.org/10.1183/09031936.00120908
  15. World Health Organization. Global tuberculosis report 2024. Available from: https://iris.who.int/bitstream/handle/10665/379339/9789240101531-eng.pdf?sequence=1.
  16. Ribera M, Zulaica A, Pujol C, et al. Estimation of the prevalence of latent tuberculosis infection in patients with moderate to severe plaque psoriasis in Spain: the Latent study. Actas Dermosifiliogr 2015;106:823-9. DOI: https://doi.org/10.1016/j.adengl.2015.10.014
  17. Garziera G, Morsch ALB, Otesbelgue F, et al. Latent tuberculosis infection and tuberculosis in patients with rheumatic diseases treated with anti-tumor necrosis factor agents. Clin Rheumatol 2017;36:1891-6. DOI: https://doi.org/10.1007/s10067-017-3714-6
  18. Torres T, Brembilla NC, Langley RG, et al. Treatment of psoriasis with biologic and non-biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: recommendations from a SPIN-FRT expert consensus. J Eur Acad Dermatology Venereol 2025;39:52-69. DOI: https://doi.org/10.1111/jdv.20287

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2025 The Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.